Testing antiarrhythmic drugs for atrial fibrillation based on genetics
Official title: A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs
Run by University of Illinois Chicago · NCT02347111 · Data updated 2026-11-12
This study is testing if two different heart medications can help people with frequent atrial fibrillation based on their genetic makeup.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 162 (estimated) |
| Sponsor | University of Illinois Chicago Academic / other |
| Locations | 4 sites (Chicago, Illinois and 3 other locations) |
| Status | Recruiting |
| Started | December 31, 2020 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | August 24, 2025 |
| Trial ID | NCT02347111 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a history of symptomatic paroxysmal or persistent atrial fibrillation.
✕Probably not a fit
Patients with permanent atrial fibrillation or those who have previously undergone AF ablation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study aims to enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) to evaluate the effectiveness of two different classes of antiarrhythmic drugs (AADs), Flecainide and Sotalol. Participants will be assessed in a cross-over design to gather preliminary data on how a common genetic risk allele may influence their response to these medications. The study seeks to address the variability in treatment response and improve the understanding of genetic factors contributing to AF. Ultimately, this research could pave the way for more personalized treatment strategies for patients with AF.
Why it matters
Potential benefit: If successful, this study could lead to more effective and personalized treatment options for patients with atrial fibrillation.
How similar studies have gone: While the approach of using genetic factors to guide treatment is gaining traction, this specific study is among the first to directly test the impact of genetic risk alleles on the response to antiarrhythmic drugs in AF.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years of age * History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF * ECG that was recorded within 1 month of randomization showing AF * Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD * Able to give informed consent Exclusion Criteria: * Permanent AF or isolated atrial flutter * Cardiac or thoracic surgery within the previous 6 months * Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital) * Medical condition that is likely to be fatal in less than one year * A history of prior AF ablation * Have already been tried on 2 or more AADs in the past for AF * Creatinine clearance \<40 ml/min * Left ventricular ejection fraction \< 50% * Contra-indication to a Class I AAD e.g., structural heart disease, or history of MI * Contra-indication to a Class III AAD, e.g., congenital or acquired long QT syndrome with QTc\>480 ms in females and \>460 ms in males at baseline * A reversible cause of AF (e.g., hyperthyroidism) * Females who are pregnant or nursing * History of severe AV node dysfunction unless an electronic pacemaker is present * First- or second-degree relative has already participated in the study * Unable to adhere to study procedures that are strictly for research purposes
Where it's running
-
University of Illinois at Chicago
Chicago, Illinois, United States Recruiting -
Jesse Brown VA Medical Center
Chicago, Illinois, United States Not yet recruiting -
Rush University Medical Center
Chicago, Illinois, United States Not yet recruiting -
Advocate Christ Medical Center
Oak Lawn, Illinois, United States Not yet recruiting
Study contacts
- Study coordinator: Dawood Darbar, M.D.
- Email: darbar@uic.edu
- Phone: 6158879032
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
-
Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II
This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.
-
4D intracardiac echocardiography to guide left atrial appendage occlusion procedures
A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.
-
Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium
This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.